| 查看: 435 | 回复: 0 | |||
[交流]
The basis of submission中的basis该怎样理解？
|
|
1.Basis of Submission for an ANDA for a Generic Drug that is the Same as its RLD When an applicant submits an ANDA for a generic drug that is the same as its RLD, the basis of submission is the RLD. Accordingly, the name of the RLD, including dosage form and strength, and its application number should be provided as the basis of submission on Form FDA 356h (i.e., the form that accompanies regulatory submissions by an applicant) and in the appropriate sections of the ANDA. 发自小木虫Android客户端 |
回复此楼» 猜你喜欢
干货分享 | 活性氧ROS的流式检测
已经有1人回复
-
点亮模型第16期 | 博莱霉素致大鼠间质性肺病模型的构建
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有294人回复
-
干货分享 ｜PCR和凝胶电泳实验结果常见问题及原因分析
已经有0人回复
-
文献分享 | 关于T细胞的相关研究
已经有5人回复
-
文献分享 | Nature综述：中山大学团队阐述靶向肿瘤活性氧（ROS）的原理与策略
已经有5人回复
-
生防菌的盆栽防效实验
已经有1人回复
-
请教大佬扩散问题
已经有5人回复
-
中文投稿“肿瘤免疫”相关
已经有6人回复
-
2025年药学专业求调剂
已经有1人回复